Evidence map›Paper›PMID 21209084›Full record

ArticleThe Journal of biological chemistry2011

Carboxyl terminus of apolipoprotein A-I (ApoA-I) is necessary for the transport of lipid-free ApoA-I but not prelipidated ApoA-I particles through aortic endothelial cells.

Pascale M Ohnsorg, Lucia Rohrer, Damir Perisa, Andreas Kateifides, Angeliki Chroni, Dimitris Kardassis, Vassilis I Zannis, Arnold von Eckardstein

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
3.8field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 26 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Lymphatic transport of high-density lipoproteins and chylomicrons.The Journal of clinical investigation · 2014
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 3 countries.

Pascale M OhnsorgFrom the Institute of Clinical Chemistry, University Hospital of Zurich, 8091 Zurich, Switzerland,; the Competence Center for Systems Physiology and Metabolic Diseases, ETH and University of Zurich, 8091 Zurich, Switzerland.
Lucia RohrerFrom the Institute of Clinical Chemistry, University Hospital of Zurich, 8091 Zurich, Switzerland,; the Center for Integrative Human Physiology, University of Zurich, 8091 Zurich, Switzerland.
Damir PerisaFrom the Institute of Clinical Chemistry, University Hospital of Zurich, 8091 Zurich, Switzerland,; the Center for Integrative Human Physiology, University of Zurich, 8091 Zurich, Switzerland.
Andreas KateifidesMolecular Genetics, Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston, Massachusetts 02118,; the Department of Biochemistry, Division of Basic Sciences, Institute of Molecular Biology and Biotechnology, University of Crete Medical School, 71201 Crete, Greece.
Angeliki Chronithe National Centre of Scientific Research "Demokritos," Institute of Biology, 15310 Athens, Greece, and.
Dimitris Kardassisthe Department of Biochemistry, Division of Basic Sciences, Institute of Molecular Biology and Biotechnology, University of Crete Medical School, 71201 Crete, Greece.
Vassilis I ZannisMolecular Genetics, Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston, Massachusetts 02118,; the Department of Biochemistry, Division of Basic Sciences, Institute of Molecular Biology and Biotechnology, University of Crete Medical School, 71201 Crete, Greece.
Arnold von EckardsteinFrom the Institute of Clinical Chemistry, University Hospital of Zurich, 8091 Zurich, Switzerland,; the Competence Center for Systems Physiology and Metabolic Diseases, ETH and University of Zurich, 8091 Zurich, Switzerland,; the Center for Integrative Human Physiology, University of Zurich, 8091 Zurich, Switzerland,. Electronic address: arnold.voneckardstein@usz.ch.
University of Crete · GRSwiss Integrative Center for Human Health · CHNational Centre of Scientific Research "Demokritos" · GRUniversity Hospital of Zurich · CHUniversity of Zurich · CH

Funding

MOLECULAR AND FUNCTIONAL ANALYSIS OF HUMAN APOA-IR01HL048739 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI ZANNIS, VASSILIS I · 1994 to 2011
$4.3M
NHLBI NIH HHS HL48739NHLBI NIH HHS R01 HL048739
6 · The paper itself

Abstract

High density lipoproteins (HDL) and apolipoprotein A-I (apoA-I) must leave the circulation and pass the endothelium to exert their atheroprotective actions in the arterial wall. We previously demonstrated that the transendothelial transport of apoA-I involves ATP-binding cassette transporter (ABC) A1 and re-secretion of lipidated particles. Transendothelial transport of HDL is modulated by ABCG1 and the scavenger receptor BI (SR-BI). We hypothesize that apoA-I transport is started by the ABCA1-mediated generation of a lipidated particle which is then transported by ABCA1-independent pathways. To test this hypothesis we analyzed the endothelial binding and transport properties of initially lipid-free as well as prelipidated apoA-I mutants. Lipid-free apoA-I mutants with a defective carboxyl-terminal domain showed an 80% decreased specific binding and 90% decreased specific transport by aortic endothelial cells. After prior cell-free lipidation of the mutants, the resulting HDL-like particles were transported through endothelial cells by an ABCG1- and SR-BI-dependent process. ApoA-I mutants with deletions of either the amino terminus or both the amino and carboxyl termini showed dramatic increases in nonspecific binding but no specific binding or transport. Prior cell-free lipidation did not rescue these anomalies. Our findings of stringent structure-function relationships underline the specificity of transendothelial apoA-I transport and suggest that lipidation of initially lipid-free apoA-I is necessary but not sufficient for specific transendothelial transport. Our data also support the model of a two-step process for the transendothelial transport of apoA-I in which apoA-I is initially lipidated by ABCA1 and then further processed by ABCA1-independent mechanisms.

Indexed as

Models, BiologicalAnimalsAortaApolipoprotein A-IATP-Binding Cassette TransportersATP Binding Cassette Transporter, Subfamily G, Member 1CattleCell LineEndothelial CellsHumansMutationProtein Processing, Post-TranslationalProtein Structure, TertiaryProtein TransportScavenger Receptors, Class BStructure-Activity RelationshipABCG1 protein, humanApolipoprotein A-IATP-Binding Cassette TransportersATP Binding Cassette Transporter, Subfamily G, Member 1SCARB1 protein, humanScavenger Receptors, Class B

Identifiers

PMID21209084
PMCPMC3048662
OpenAlexW2039697717

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.